Prescription medications often come with a long list of side effects. If you’ve ever seen a commercial for a new medication, you’ve probably heard a litany of possible side effects that come with the medication. Some often make people wonder if the side effects or the condition the medication treats is the lesser of two evils.
The FDA recently added new warning labels to two similar medications, AstraZeneca’s Onglyza and Takeda’s Nesina. The addition came after a safety review revealed increased risk for a heart attack with the two diabetes medications.
The addition of the warning label came after a 2015 recommendation from an FDA advisory committee to add the warning. The decision was made after data from two large clinical trials caused the regulator’s decision to issue the alert.
Onglyza and Nesina are two varieties of a type of diabetes medication. They are known as dipeptidyl peptidase-4 (DPP-4) inhibitors.
The FDA reviewed two studies of the two drugs before making the move. One study involved 16,492 patients with Type 2 diabetes. In that study, 3.5% of Onglyza-treated patients were hospitalized with heart failure. Only 2.8% of placebo-treated patients were hospitalized with the same condition. The Nesina study involved 5,380 patients. Of those, 3.9% of the Nesina-treated patients were hospitalized, compared to 3.3% of the placebo-treated patients.
FDA officials considered the results of the second study to be insignificant and were more concerned with the results of the Onglyza study. However, because both drugs are DPP-4 inhibitors and work in the same fashion, they decided to place warnings on both drugs.
If you have suffered heart failure or another adverse health event due to taking the prescribed drug Onglyza, you may be entitled to compensation. Contact the law offices of John Foy & Associates. Our “Strong Arm” attorneys will help to get you the compensation you deserve. Contact us today.